Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCryst Pharmaceuticals has secured a $34.7m contract from the US Centers for Disease Control and Prevention (CDC) for the supply of up to 50,000 doses of its approved antiviral influenza therapy, RAPIVAB (peramivir injection) over a five-year period.
Image: Exterior view of CDC′s Roybal campus in Atlanta, Georgia. Photo: courtesy of James Gathany, Centers for Disease Control and Prevention/Wikipedia.org.
Subscribe to our email newsletter
The CDC’s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency.
BioCryst CEO Jon Stonehouse said: “We appreciate the CDC acknowledging the value of RAPIVAB to patients and our national security.
“Peramivir continues to be a source of non-dilutive capital for BioCryst and we will use these additional resources to support advancement of our exciting pipeline,” Stonehouse added.
Source: Company Press Release
